Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

医学 内科学 安慰剂 肿瘤科 肺癌 病理 替代医学
作者
Marina Chiara Garassino,Shirish M. Gadgeel,Delvys Rodríguez‐Abreu,Enriqueta Felip,Emilio Esteban,Giovanna Speranza,Maximilian J. Hochmair,Steven Powell,Edward B. Garon,Rina Hui,Naoyuki Nogami,Răzvan Cristescu,Michael Morrissey,Andrey Loboda,Julie Kobie,Mark Ayers,Bilal Piperdi,M. Catherine Pietanza,Alexandra Snyder,Martin Reck
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:38 (15_suppl): 9521-9521 被引量:24
标识
DOI:10.1200/jco.2020.38.15_suppl.9521
摘要

9521 Background: In a previous analysis of KEYNOTE-189 (NCT02578680), we showed that tissue TMB (tTMB) assessed by whole-exome sequencing was not significantly associated with efficacy in either arm and that pembro + chemo improved outcomes vs placebo + chemo in both the tTMB ≥175 and tTMB < 175 mut/exome subgroups. Here, we explored the association of bTMB with efficacy in KEYNOTE-189. Methods: 616 patients (pts) were randomized 2:1 to pembro + chemo or placebo + chemo. bTMB was assessed in cfDNA using the Guardant Health Omni assay. Association of bTMB (continuous square root transformed) with outcomes in each arm was assessed using Cox proportional hazards models (OS, PFS) and logistic regression (ORR) adjusted for ECOG PS; statistical significance was determined at the 0.05 level without multiplicity adjustment. The clinical utility of bTMB on outcomes was assessed using the cutoff that most closely approximated the 175 mut/exome tTMB cutoff as determined by AUROC analysis. Data cutoff was 21 Sep 2018. Results: 235 (38%) treated pts had evaluable tTMB and bTMB: 160 in the pembro + chemo arm and 75 in the placebo + chemo arm. bTMB as a continuous variable was not significantly associated with OS or ORR for pembro + chemo (one-sided P = .229 and .051) or placebo + chemo (two-sided P = .641 and .069); bTMB was significantly associated with PFS in the pembro + chemo arm (one-sided P = .015) but not the placebo + chemo arm (two-sided P = .058). bTMB and tTMB scores were moderately correlated (r = .61). The bTMB cutoff that most closely approximated tTMB 175 mut/exome was 15 mut/Mb (AUROC 0.81, 95% CI 0.75-0.86). 178 (76%) pts had concordant bTMB and tTMB results—101 low and 77 high by both—whereas 57 (24%) had discordant results—21 high bTMB but low tTMB, 36 low bTMB but high tTMB. Pembro + chemo improved OS, PFS, and ORR vs placebo + chemo for bTMB ≥15 and < 15 mut/exome (Table). Conclusions: Similar to previous findings based on tTMB, bTMB has limited clinical utility in the setting of pembro with pemetrexed and platinum given as first-line therapy for metastatic nonsquamous NSCLC. Clinical trial information: NCT02578680 . [Table: see text]

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
补兑补完成签到,获得积分10
1秒前
1秒前
2秒前
3秒前
MRCHONG发布了新的文献求助10
3秒前
搜集达人的应助被暮离采纳,获得10
4秒前
4秒前
已知发布了新的文献求助10
4秒前
时嗷完成签到,获得积分10
5秒前
苹果南烟发布了新的文献求助10
5秒前
5秒前
quan发布了新的文献求助10
6秒前
6秒前
6秒前
思源的应助被正在采纳,获得10
7秒前
云岚发布了新的文献求助10
7秒前
8秒前
雪山大地发布了新的文献求助10
8秒前
Ternura发布了新的文献求助10
8秒前
桐桐的应助被孤独的冷安采纳,获得10
9秒前
9秒前
秽鸢鸠梦发布了新的文献求助10
10秒前
yyyyyy发布了新的文献求助10
11秒前
自由初蝶的应助被结实的翠芙采纳,获得30
11秒前
小明同学发布了新的文献求助10
11秒前
科研通AI6.4的应助被jerry采纳,获得10
12秒前
12秒前
李爱国的应助被拖鞋采纳,获得10
12秒前
12秒前
健壮璎发布了新的文献求助10
13秒前
少双发布了新的文献求助10
13秒前
13秒前
14秒前
急着写论文的毕业生完成签到 ,获得积分10
14秒前
嘻嘻完成签到,获得积分10
14秒前
脑洞疼的应助被Whywhy采纳,获得10
15秒前
16秒前
huakeguanli发布了新的文献求助10
16秒前
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008